Navigation Links
Telik Announces Financial Results for 2008 Third Quarter
Date:11/5/2008

ug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements, including statements regarding Telik's future development of TELINTRA and TELCYTA. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, if clinical trials of TELINTRA or TELCYTA are delayed or unsuccessful, Telik's business would suffer, if Telik's competitors develop and market products that are more effective than its product candidates or any product that Telik may develop, or obtain marketing approval before Telik does, Telik's commercial opportunity will be reduced or eliminated, and if Telik does not obtain regulatory approval to market products in the U.S. and foreign countries, Telik will not be permitted to commercialize its product candidates. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended June 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, In
'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
2. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
3. Telik Announces Receipt of Nasdaq Notice
4. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
5. ReceptorBio Announces Diabetes License Agreement With Telik
6. Telik Announces Financial Results For 2008 Second Quarter
7. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
8. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. Telik Announces First Quarter 2008 Financial Results
11. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Nematicide is a ... Nematodes are microscopic parasitic roundworms, found in massive ... other plants and animals. Nematicides have tended to ... properties promoting migration through the soil. A single ... plant-parasitic nematodes. With more than 10,000 species classified, ...
(Date:9/30/2014)... Follow us on LinkedIn –Cholesterol ... cholesterol carrier or lipoprotein in the blood. Such tests ... in the body, especially along the walls of blood ... other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading ... on a regular basis, to assess an individual’s risk ...
(Date:9/30/2014)... September 30, 2014 Fast, ... of chemistry in documents ChemAxon ... and consulting services for life science research, launches ... generate Markush structures from documents. Markush ... property, however generating and understanding Markush structures is ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... Dec. 9 The results of a new study on ... 30 sites around the country, will be published in the ... Salloway, MD, MS, director of the Butler Hospital Memory and ... the Warren Alpert Medical School of Brown University, says that ...
... , SAN DIEGO, Dec. 9 ... life-saving medicines specifically designed to enhance the perfusion and ... and other gas delivery, today announced that the European ... MP4CO for the treatment of sickle cell disease. This ...
... ... Platform for High Throughput and High Content Screening. , ... Basel, Switzerland and Granada, Spain (PRWEB) December 8, ... discovery and life science research, and Fundación MEDINA (Centro de Excelencia en ...
Cached Biology Technology:Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4
(Date:9/30/2014)... think of nature as something that we enjoy when we ... Or do we think of ourselves as a part of ... what about a house? , The answers to these ... our actions, our speech and in cultural artifacts. , A ... Washington, the American Indian Center of Chicago and the Menominee ...
(Date:9/30/2014)... WASHINGTON, D.C., September 30, 2014--Sea monkeys have captured the ... of their easily observable life cycle -- sold as ... and mate given little more than a tank of ... a shorter-term pattern: Like other zooplankton, brine shrimp vertically ... conditions, coming closer to the surface at night and ...
(Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
Breaking Biology News(10 mins):The cultural side of science communication 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... anywhere, a researcher at the Hebrew University of Jerusalem has ... the brain of a mammal. , Dr. Adi Mizrahi ... of Life Sciences at the Hebrew University, used mouse models ... undifferentiated cellular sphere into a rich and complex cell. This ...
... cure type 1 diabetes by allowing people to ... defective pancreas, medical researchers here have reported that they ... cord blood to produce insulin. , The researchers announced ... research, in the June 2007 issue of the medical ...
... organism that produces the world’s most lethal toxin is revealed today. ... Clostridium botulinum and less than 2 kg — the weight of ... on the planet. Very small amounts of the same toxin are ... , The genome sequence shows that C. botulinum doesn’t have subtle ...
Cached Biology News:A first -- Hebrew University scientist observes brain cell development in 'real time' 2Adult stem cells from human cord umbilical cord blood successfully engineered to make insulin 2Adult stem cells from human cord umbilical cord blood successfully engineered to make insulin 3Genome of Clostridium botulinum reveals the background to world's deadliest toxin 2Genome of Clostridium botulinum reveals the background to world's deadliest toxin 3
... Immunogen: synthetic peptide corresponding to the ... dopamine receptor, conjugated to KLH. The ... rat and mouse gene. Physical form: ... containing 0.01% sodium azide. Titertest method: ...
... The National Collection of Pathogenic ... authenticated human pathogenic viruses in ... is able to supply the ... from them, to the scientific ...
... The flexible and easy ... used to control all members ... family. It features a clear ... visual assay setup, user-friendly and ...
Roll of Mesh 5m x 25cm...
Biology Products: